- 7/24 Live Call Center
Last Updated on November 27, 2025 by Bilal Hasdemir
We are seeing big changes in prostate cancer care. New research and technology are leading the way. Studies show that new therapies, like radioligand therapies, are very effective. They target cancer cells well and help patients live longer.
At Liv Hospital, we aim to give top-notch healthcare to all patients. We make sure everyone gets the latest and best treatments.
Therapies like 177Lu-PSMA-617 (Pluvicto®) are making a big difference. They deliver targeted radiation to cancer cells. This helps slow down the cancer’s growth.
In 2025, prostate cancer treatment is changing a lot. Now, we focus more on precision medicine and targeted therapies. This makes treatments better and more specific.
Prostate cancer is a big problem for men all over the world. Every year, over 1.4 million new cases are found. Thanks to new research and tech, treatments are getting better.
But, there are still big challenges:
The move to precision medicine has changed how we treat prostate cancer. Now, treatments are made just for each patient. This leads to better results.
Some big steps in precision medicine for prostate cancer are:
These new methods have changed the way we treat prostate cancer. At Liv Hospital, we use the latest tech and treatments. Our goal is to give cutting-edge prostate cancer care and better outcomes for our patients.
Knowing about prostate cancer stages is key to making good treatment plans. Prostate cancer is a complex disease needing a careful treatment plan. We focus on managing the disease and keeping quality of life in mind.
In early-stage prostate cancer, we aim to remove or control the cancer while saving healthy tissue. Treatments might include active surveillance, surgery, or radiation. For advanced cancer, we use stronger treatments to manage symptoms and slow the disease.
Research shows that matching treatments to the cancer stage is vital for the best results. For example, a study in the Daily Mail talked about how radiation therapy is used in prostate cancer treatment. It shows the need for precise treatment plans.
Quality of life is very important in prostate cancer treatment, no matter the stage. We aim to reduce side effects and keep patients’ functions good. Important factors include:
We offer innovative prostate cancer treatment options to meet each patient’s needs. Our team works together to create personalized plans.
Effective prostate cancer treatment needs a deep understanding of the disease stage. We combine the latest medical knowledge with a focus on the patient. This way, we aim to give our patients the best care possible.
Prostate cancer treatment has seen a big leap forward with 177Lu-PSMA-617 (Pluvicto®). This new method has changed how we treat advanced prostate cancer. It brings new hope to those with metastatic disease.
Radioligand therapy targets prostate-specific membrane antigen (PSMA) on cancer cells. It uses a ligand that binds to PSMA, linked to a radioactive isotope (Lutetium-177). This complex goes inside cancer cells, delivering radiation directly to them while sparing healthy tissues.
Key advantages of this targeted approach include:
Clinical trials show 177Lu-PSMA-617’s ability to shrink tumors and slow disease growth in metastatic prostate cancer. It has shown great promise in improving survival and quality of life.
“The results from the VISION trial highlighted the potential of 177Lu-PSMA-617, showing a significant reduction in the risk of radiographic progression or death.”
A summary of clinical outcomes is presented in the following table:
| Trial | Patient Cohort | Outcome |
| VISION | Metastatic castration-resistant prostate cancer | Significant reduction in radiographic progression or death |
| Phase II Study | Patients with PSMA-positive metastatic disease | High response rates and improved survival |
Choosing patients for 177Lu-PSMA-617 therapy involves checking PSMA expression through PET scans. Those with high PSMA expression are best candidates. The treatment involves cycles, with the number based on patient response and tolerance.
At Liv Hospital, we offer a personalized approach to care. Our team ensures each patient gets a tailored treatment plan. We work closely with patients to find the best treatment protocol, maximizing therapy benefits.
New hormone therapies are changing how we treat prostate cancer. They offer hope to those affected. These treatments come from deep research into how prostate cancer grows and how it resists old treatments.
Advanced androgen receptor inhibitors are showing great promise. They work well against prostate cancer that doesn’t respond to traditional treatments. These inhibitors block the androgen receptor, which is key for prostate cancer cells to grow.
Key Features:
Examples include enzalutamide and apalutamide. They have shown real benefits in clinical trials.
Castration-resistant prostate cancer (CRPC) is when cancer keeps growing even with hormone therapy. New hormone therapies aim to tackle CRPC by:
How we sequence hormone therapies is key to success. We must plan the order of these treatments carefully. This ensures they work best and reduces the chance of resistance.
| Therapy Sequence | Clinical Benefit |
| First-line: Abiraterone | Improved overall survival |
| Second-line: Enzalutamide | Delayed disease progression |
| Third-line: Chemotherapy | Management of advanced disease |
Heat shock protein inhibitors are a cutting-edge approach in fighting prostate cancer. They offer new hope for patients. These therapies target survival mechanisms in cancer cells, helping those who resist other treatments.
Heat shock proteins help keep proteins stable in cells. In cancer, these proteins are too high, helping tumors grow and resist treatment. NXP800 and similar therapies aim to stop this by blocking heat shock proteins.
These inhibitors work by selectively targeting specific heat shock proteins. This helps control the stress response in cells. It aims to protect normal cells while fighting cancer.
Early trials of NXP800 and similar inhibitors show promise in advanced prostate cancer. They suggest these agents could offer benefits, especially when other treatments fail.
The initial results are encouraging. They show heat shock protein inhibitors might be a new option for therapy-resistant prostate cancer. More trials are needed to fully understand their safety and effectiveness.
Heat shock protein inhibitors mark a big step forward in treating therapy-resistant prostate cancer. They target survival pathways, helping to overcome resistance to current treatments. This gives hope to patients with few options.
As research grows, heat shock protein inhibitors will become more vital in cutting-edge prostate cancer care. They might be used with other treatments, improving outcomes. This could lead to a more effective way to fight this complex disease.
PARP inhibitors are a big step forward in treating prostate cancer. They work well for patients with certain DNA repair mutations, especially BRCA1/2 changes.
Genetic changes in BRCA1 and BRCA2 genes raise the risk of prostate cancer. PARP inhibitors target the tumor’s DNA damage issue, causing cell death. Research shows they help patients with these mutations a lot.
“The introduction of PARP inhibitors in prostate cancer treatment has been a major breakthrough,” says a top oncologist.
“These targeted therapies have shown significant promise in clinical trials, providing a much-needed treatment option for patients with genetically-defined prostate cancer.”
There are several PARP inhibitors for prostate cancer, like olaparib and rucaparib. These drugs are approved for patients with mCRPC and BRCA1/2 mutations. More studies are looking at their use in different prostate cancer cases.
We aim to make these advanced treatments available to our patients. Our team helps choose the best treatment based on each patient’s genetic makeup and cancer type.
Genetic testing is key to finding the right patients for PARP inhibitors. We suggest genetic testing for all advanced prostate cancer patients to check for BRCA1/2 and other DNA repair mutations. This helps guide treatment choices and ensures patients get the best care.
By using genetic testing, we can tailor care to each patient’s needs. Our team is committed to exploring new prostate cancer treatments, including PARP inhibitors.
Immunotherapy is changing how we treat prostate cancer. It uses the body’s immune system to fight cancer. This shift in treatment is making a big difference in patient care.
Checkpoint inhibitors are a new hope for cancer treatment, including prostate cancer. They help the immune system fight cancer cells better. This approach is now being used in clinics, giving patients new hope.
Therapies like pembrolizumab and nivolumab have shown great promise in trials. Some patients have seen long-lasting benefits. But, not everyone responds the same way. Scientists are working to find out who will benefit most.
Therapeutic cancer vaccines are another exciting area of research. They aim to treat cancer by boosting the immune system. Sipuleucel-T is one vaccine approved for advanced prostate cancer.
These vaccines target specific proteins on cancer cells. This helps the immune system attack cancer more effectively. Researchers are working to make these vaccines better and to use them with other treatments.
Cellular therapies, like CAR-T cell therapy, are being explored for prostate cancer. They modify T cells to attack cancer cells. Early results are promising, especially for advanced cases.
As immunotherapy advances, we’re committed to offering our patients the latest treatments. Immunotherapy is changing prostate cancer care, bringing new hope and better outcomes.
New advances in prostate cancer treatment show the power of combination therapy approaches. Mixing different treatments can lead to synergistic effects, making treatments better. We aim to manage side effects well, so patients get the best care with fewer problems.
Using different treatments together seems to help prostate cancer patients more. For example, mixing radioligand therapy with next-generation hormone therapies can make treatments work better. Research shows these combos can improve survival and quality of life.
Choosing between sequential or concurrent therapy depends on many things. Sequential therapy means treatments are given one after another. Concurrent therapy means treatments are given at the same time.
“The optimal sequencing of treatments is crucial to maximizing their effectiveness while minimizing toxicity.” – Expert in Prostate Cancer Treatment
We look at each patient’s situation to decide the best therapy. We think about how treatments work together and the risk of side effects.
One big challenge in using combination therapy is dealing with side effects. We work hard to reduce these by:
By balancing the good and bad of combination therapy, we can give our patients the best treatments for advanced prostate cancer.
Advanced diagnostic technologies are key in guiding prostate cancer treatment. We’re moving towards precision medicine fast. This is thanks to cutting-edge tools that offer more accurate and personalized care.
PSMA-PET scanning is changing how we stage prostate cancer. It lets us find metastatic disease more accurately. This helps tailor treatments to each patient’s needs.
Studies show PSMA-PET scanning is more accurate than old methods. It’s vital for deciding between local or systemic treatments.
Genomic and biomarker testing are key in prostate cancer care. They find genetic mutations for targeted therapies. For example, the biopsy devices market is growing, helping with more precise testing.
| Biomarker | Clinical Utility |
| BRCA1/2 | Predictive marker for PARP inhibitors |
| AR expression | Predictive marker for hormone therapies |
| MSI | Predictive marker for immunotherapy |
Artificial intelligence (AI) is being used more in prostate cancer treatment planning. AI looks at big data to find patterns that doctors might miss. This helps in personalized treatment planning.
“The integration of AI in prostate cancer care represents a significant step forward in our ability to provide personalized and effective treatment options.” – An Oncologist
Getting advanced prostate cancer treatments involves knowing a few key things. As we improve how we treat prostate cancer, it’s important for patients to know what affects their access to new treatments.
Understanding insurance is a big step in getting new prostate cancer treatments. We help patients figure out their insurance and find ways to make treatments more affordable.
Clinical trials give patients a chance to try the newest innovative prostate cancer treatment options. We think clinical research is key and help find trials that might be right for our patients.
For some, getting treatment abroad might be a good choice. We’ve teamed up with top cancer centers worldwide. This lets us help patients get advanced treatments no matter where they are.
Our commitment is to make sure every patient can get the latest prostate cancer treatments, no matter where they are.
Knowing how to get to cutting-edge prostate cancer treatments helps patients make better choices. We’re here to support our patients every step of the way.
At Liv Hospital, we use the latest medical tech and tailor care to each patient. We aim to give top-notch healthcare and support to international patients. This ensures they get the best treatments available.
Liv Hospital follows global medical standards and protocols. This means our patients get care from a team of experts. Our focus on these standards helps our patients get the latest in advanced prostate cancer therapies.
We keep our treatment plans up-to-date with the newest prostate cancer care. This way, our patients get access to the latest treatments.
| Treatment Aspect | Liv Hospital’s Approach |
| Diagnostic Techniques | State-of-the-art imaging and genomic testing |
| Treatment Options | Includes radioligand therapy, next-generation hormone therapies, and PARP inhibitors |
| Patient Support | Comprehensive support services including counseling and financial assistance guidance |
Our teams at Liv Hospital work together to create personalized treatment plans. We use the latest and most innovative therapies. This team effort ensures every patient gets the best care, from start to finish.
“The collaboration between oncologists, radiologists, and other specialists at Liv Hospital ensures that our patients receive comprehensive care that addresses all their needs.”
Dealing with cancer care can be tough and emotional. That’s why we offer full support services. Our help includes counseling, financial guidance, and help with travel for international patients.
By combining advanced prostate cancer therapies with caring and support, Liv Hospital aims to better outcomes and quality of life for our patients.
Dealing with prostate cancer treatment can be tough. But, with the right help, patients can find the best treatments. At Liv Hospital, we offer full support and guidance. This ensures our patients get the care they need.
Research shows how crucial patient education and support are. It’s important to have all the resources and guidance needed. We stay updated with medical advancements and follow international standards. This helps us improve our patients’ outcomes and quality of life.
Our goal is to provide the latest prostate cancer treatments. This way, our patients can get the best therapies and achieve great results.
New treatments include radioligand therapy and next-generation hormone therapies. We also have heat shock protein inhibitors, PARP inhibitors, and immunotherapy. Our goal is to provide the best care with the latest medical advancements.
Radioligand therapy, like 177Lu-PSMA-617 (Pluvicto®), targets cancer cells with radiation. It offers hope for those with advanced disease. This therapy is available at Liv Hospital.
Hormone therapy is key in treating prostate cancer. New therapies are more effective and easier to handle. We choose the right treatments to improve life quality and outcomes.
Heat shock protein inhibitors target cancer cells’ survival mechanisms. They offer hope for those resistant to other treatments. We’re keeping up with the latest research in this area.
PARP inhibitors are a big step forward in treating prostate cancer, especially for those with certain genetic mutations. We emphasize genetic testing to find the right patients for these therapies.
Immunotherapy is a promising area in prostate cancer research. It has shown great potential. We’re committed to exploring these options to improve life quality and outcomes.
Combination therapy uses different treatments together for better results. We manage side effects carefully to ensure safety.
We use advanced tools like PSMA-PET scanning and genomic testing. Artificial intelligence helps us make more precise treatment plans.
At Liv Hospital, we help patients get the latest treatments. This includes insurance guidance, clinical trial info, and international options.
We provide comprehensive support to help patients through cancer care. Our teams work together to create personalized treatment plans with the latest therapies.
Prostate Cancer Foundation (PCF): New Drug Hope for Prostate Cancer Patients
